Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA7 | P43166 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140476 | 0.86 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14674137 | 0.85 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17926251 | 0.83 | TYR (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28126806 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL39010 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15782801 | 0.83 | HSD17B1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9959316 | 0.82 | CA2 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27658957 | 0.82 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27517848 | 0.82 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3873135 | 0.82 | CA12 (0.55) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016008862-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | WO | disclosed |
| CN-102361857-B | Can be used as the ring-type benzimidizole derivatives of antidiabetic | MERCK SHARP & DOHME CORP. (US) | 2015-09-16 | — | — | CN | disclosed |
| WO-2012139891-A1 | SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| CN-101941964-A | Has the Chemokine Receptors bonded heterogeneous ring compound that promotes effect | ANORMED INC | 2011-01-12 | — | — | CN | disclosed |
| CN-1826310-B | Novel aminobenzophenone compounds | LEO PHARMA AS | 2010-07-21 | — | — | CN | disclosed |
| CN-101426786-A | Benzazole potentiators of metabotropic glutamate receptors | MERCK & CO INC (US) | 2009-05-06 | — | — | CN | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| CN-1282636-C | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2006-11-01 | — | — | CN | disclosed |
| WO-2006091496-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| CN-1826310-A | Novel aminobenzophenone compounds | LEO PHARMA AS (DK) | 2006-08-30 | — | — | CN | disclosed |
| CN-1332711-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2002-01-23 | — | — | CN | disclosed |
| US-3985797-A | Hydroxylation of aromatic compounds | UOP INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3985796-A | Hydroxylation of aromatic compounds | UOP INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3931295-A | Hydroxylation of aromatic compounds | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | CA12 4211/4885CA1 2573/4885CA2 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.